Robert E. Sammelson
University of California, Davis
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Robert E. Sammelson.
Bioorganic & Medicinal Chemistry Letters | 2003
Robert E. Sammelson; Tonghui Ma; Luis J. V. Galietta; A. S. Verkman; Mark J. Kurth
A novel class of activators for chloride conductance in the cystic fibrosis transmembrane conductance regulator (CFTR) protein has been identified. These 3-(2-benzyloxyphenyl)isoxazoles and 3-(2-benzyloxyphenyl)isoxazolines were synthesized employing the 1,3-dipolar cycloaddition of nitrile oxides with various alkene and alkyne dipolarophiles. Utilizing a fluorescence cell-based assay of halide transport, the best compounds increased CFTR-dependent chloride transport with half-maximal stimulation at 20-50 microM.
Tetrahedron Letters | 2001
Robert E. Sammelson; Mark J. Kurth
Abstract We have established that using an oxidation-Cope elimination cleavage protocol allows for the synthesis of N , N -disubstituted hydroxylamines from REM resin (polymer-bound benzyl acrylate). Michael addition of a secondary amine or addition of a primary amine followed by reductive alkylation provides polymer-bound tertiary amines. Oxidation of these resin-bound tertiary amines with MCPBA is followed by concomitant Cope elimination to regenerate the polymer-bound acrylate and provide the cleaved hydroxylamines.
Current Pharmaceutical Biotechnology | 2014
Diana Cordero; Christopher R. Fullenkamp; Rachel R. Pelly; Katie M. Reed; Lindy M. Caffo; Ashley N. Zahrt; Micaleah Newman; Sarah Komanapalli; Evan M. Niemeier; Derron L. Bishop; Heather A. Bruns; Mark K. Haynes; Larry A. Sklar; Robert E. Sammelson; Susan A. McDowell
Staphylococcus aureus is a leading causative agent in sepsis, endocarditis, and pneumonia. An emerging concept is that prognosis worsens when the infecting S. aureus strain has the capacity to not only colonize tissue as an extracellular pathogen, but to invade host cells and establish intracellular bacterial populations. In previous work, we identified host CDC42 as a central regulator of endothelial cell invasion by S. aureus. In the current work, we report that ML 141, a first-in-class CDC42 inhibitor, decreases invasion and resultant pathogenesis in a dose-dependent and reversible manner. Inhibition was found to be due in part to decreased remodeling of actin that potentially drives endocytic uptake of bacteria/fibronectin/integrin complexes. ML 141 decreased binding to fibronectin at these complexes, thereby limiting a key pathogenic mechanism used by S. aureus to invade. Structural analogs of ML 141 were synthesized (designated as the RSM series) and a subset identified that inhibit invasion through non-cytotoxic and non-bactericidal mechanisms. Our results support the development of adjunctive therapeutics targeting host CDC42 for mitigating invasive infection at the level of the host.
Chemical Reviews | 2001
Robert E. Sammelson; Mark J. Kurth
Journal of Agricultural and Food Chemistry | 2003
Pierluigi Caboni; Robert E. Sammelson; John E. Casida
Bioorganic & Medicinal Chemistry | 2004
Robert E. Sammelson; Pierluigi Caboni; Kathleen A. Durkin; John E. Casida
American Journal of Physiology-lung Cellular and Molecular Physiology | 2003
Emanuela Caci; Chiara Folli; Olga Zegarra-Moran; Tonghui Ma; Mark F. Springsteel; Robert E. Sammelson; Michael H. Nantz; Mark J. Kurth; A. S. Verkman; Luis J. V. Galietta
Journal of Organic Chemistry | 2000
Robert E. Sammelson; R. Bryan Miller; Mark J. Kurth
Journal of Organic Chemistry | 2003
Robert E. Sammelson; John E. Casida
Journal of Organic Chemistry | 2002
Robert E. Sammelson; Chamindra D. Gurusinghe; Jeffrey M. Kurth; Marilyn M. Olmstead; Mark J. Kurth